SPOTLIGHT -
This slideshow provides information about the compounds, clinically relevant attributes, approximate dose, and data under study.
OX124 for Opioid Overdose Reversal Receives FDA Complete Response Letter
How to Talk to Teenagers About Substance Use
Becoming Comfortable With Discomfort: Polypharmacy for Patients With Substance Use Disorders
Lloyd Sederer, MD: A Conversation About Addiction and the Opioid Epidemic
A Look at the Comorbidity of Eating Disorders and Addiction
First Nontobacco Flavored E-Cigarette Products Authorized by the FDA